You are here

SOD/Catalase mimics for age-related learning impairment

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: PHS2001-2
Agency Tracking Number: 1R41AG019531-01
Amount: $256,638.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2001
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
6-F ALFRED CIRCLE BEDFORD, MA 01730
BEDFORD, MA 01730
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 MICHEL BAUDRY
 (949) 824-4393
 BAUDRY@NEURO.USC.EDU
Business Contact
 MALFROY-CAMINE, BERNARD
Phone: (781) 275-0424
Email: B.MALFROY@EUKARION.COM
Research Institution
 UNIVERSITY OF SOUTHERN CALIFORNIA
 
UNIVERSITY OF WISCONSIN-MADISON
LOS ANGELES, CA 90089
United States

 Nonprofit college or university
Abstract

DESCRIPTION Adapted from applicant's abstract): Aging is accompanied by a slow
decline in cognitive function, now referred to as mild cognitive impairment
(MCI), and by accumulation of oxidized proteins and lipids as a result of
oxidative stress. Eukarion has discovered a new class of manganese complexes
that display both superoxide dismutase (SOD) and catalase activities. These
SOD/catalase mimetics have shown efficacy in several models of human diseases
in which oxidative stress has been implicated. In particular, EUK-134 has been
found to be highly protective in a rodent model for stroke and in kainic
acid-induced neuronal damage. It also reduced oxidative stress and prolonged
survival in a mouse model for ALS. The present project is directed at testing
the efficacy of EUK-134 and another analog on age-related oxidative stress and
learning and memory impairment in mice. Eight month-old mice will be treated
with EUK-134 and another analog for 3 months. They will be tested for
acquisition and retention of 2 different tasks, an avoidance learning paradigm,
and a fear-conditioning paradigm. Markers of oxidative stress will be measured
in various brain structures and correlated with behavioral measures. It is our
hope that results from these studies will demonstrate the potential therapeutic
values of EUK molecules for treating patients with MCI.
PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government